The non-neurovirulent rhinovirus:poliovirus chimera PVSRIPO was shown to synergise with anti-PD-1 and anti-PD-L1 therapy in mouse triple-negative breast cancer (TNBC) models (73) and is currently the subject of early-phase clinical trials. The gene discussed is CD274; the disease is triple-negative breast carcinoma.